EAM Global Investors LLC decreased its stake in Vericel Corp (NASDAQ:VCEL) by 8.7% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 92,899 shares of the biotechnology company’s stock after selling 8,821 shares during the period. EAM Global Investors LLC’s holdings in Vericel were worth $1,627,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Emerald Advisers LLC acquired a new position in Vericel in the first quarter worth $7,295,000. Vanguard Group Inc. boosted its stake in Vericel by 18.2% in the third quarter. Vanguard Group Inc. now owns 2,363,346 shares of the biotechnology company’s stock worth $33,441,000 after purchasing an additional 363,705 shares in the last quarter. Oberweis Asset Management Inc. boosted its stake in Vericel by 304.5% in the fourth quarter. Oberweis Asset Management Inc. now owns 383,870 shares of the biotechnology company’s stock worth $6,679,000 after purchasing an additional 288,970 shares in the last quarter. Artisan Partners Limited Partnership acquired a new position in Vericel in the first quarter worth $3,858,000. Finally, Federated Investors Inc. PA raised its position in shares of Vericel by 49,552.7% during the first quarter. Federated Investors Inc. PA now owns 200,597 shares of the biotechnology company’s stock worth $3,512,000 after acquiring an additional 200,193 shares during the last quarter. 85.22% of the stock is currently owned by institutional investors and hedge funds.

In other Vericel news, CFO Gerard J. Michel sold 17,500 shares of the stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $17.02, for a total value of $297,850.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Gerard J. Michel sold 10,000 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $20.02, for a total value of $200,200.00. Following the completion of the sale, the chief financial officer now owns 122,249 shares of the company’s stock, valued at $2,447,424.98. The disclosure for this sale can be found here. Insiders sold 50,625 shares of company stock valued at $899,750 in the last quarter. 4.50% of the stock is currently owned by corporate insiders.

VCEL has been the subject of a number of recent research reports. Zacks Investment Research downgraded Vericel from a “buy” rating to a “hold” rating in a research report on Friday, March 1st. BidaskClub downgraded Vericel from a “buy” rating to a “hold” rating in a report on Friday, March 15th. Needham & Company LLC downgraded Vericel from a “buy” rating to a “hold” rating and set a $17.92 price objective for the company. in a report on Thursday, February 28th. Finally, Oppenheimer upped their price objective on Vericel from $23.00 to $32.00 and gave the company an “outperform” rating in a report on Wednesday, May 8th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $22.98.

NASDAQ VCEL opened at $15.65 on Monday. The company has a debt-to-equity ratio of 0.24, a current ratio of 8.47 and a quick ratio of 8.16. Vericel Corp has a 12 month low of $8.95 and a 12 month high of $21.00.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07). The business had revenue of $21.81 million during the quarter, compared to the consensus estimate of $22.51 million. Vericel had a negative return on equity of 3.40% and a negative net margin of 3.51%. The firm’s revenue was up 21.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.21) earnings per share. On average, research analysts predict that Vericel Corp will post 0.05 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Vericel Corp (VCEL) Position Reduced by EAM Global Investors LLC” was reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/vericel-corp-vcel-position-reduced-by-eam-global-investors-llc/3030073.html.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.

Further Reading: What is the Ex-Dividend Date in Investing?

Want to see what other hedge funds are holding VCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vericel Corp (NASDAQ:VCEL).

Institutional Ownership by Quarter for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.